1. Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?
- Author
-
Loeb S, Gupta A, Losonczy L, Tosoian J, and Walsh PC
- Subjects
- Humans, Male, Prostatic Neoplasms mortality, Risk Factors, Survival Rate, Treatment Outcome, Adrenergic alpha-Antagonists adverse effects, Adrenergic alpha-Antagonists therapeutic use, Prostatic Hyperplasia drug therapy, Prostatic Neoplasms epidemiology
- Abstract
Purpose of Review: To determine whether alpha-blockers, commonly used for the treatment of benign prostatic hyperplasia, are associated with prostate cancer risk., Recent Findings: Alpha-blockers have been associated with a reduced risk of prostate cancer aggressiveness in some observational studies and an increased risk in other studies. However, this relationship is complex as different alpha-blockers have divergent effects in laboratory studies and there are many confounders in daily practice such as differential screening practices., Summary: Both benign prostatic hyperplasia and prostate cancer are common conditions in the aging male population, such that an interaction between alpha-blockers and prostate cancer risk is clinically relevant. Prospective evidence is necessary to establish a definitive link.
- Published
- 2013
- Full Text
- View/download PDF